BOTHELL, Wash.--(BUSINESS WIRE)--Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, announced that it has entered into a Convertible Note and Warrant Purchase Agreement with RBFSC, Inc. (“RBFSC”), a related party, resulting in gross proceeds of $3 million.
